Nucs AI is revolutionizing cancer care through cutting-edge AI and medical imaging technology. Founded in 2024 by a multidisciplinary team of oncologists, AI researchers, and healthcare innovators, we’re tackling one of medicine’s most pressing challenges: the growing demand for accurate, timely cancer diagnostics in the face of rising scan volumes and limited radiologist capacity.
We sit at the intersection of diagnostics and treatment planning—building AI-powered tools at the convergence of medical imaging, radioligand therapy, and artificial intelligence. Starting with prostate cancer and expanding across oncology, we partner with world-leading medical institutions and pharmaceutical companies across the US, Europe, and Australia to bring precision oncology into everyday clinical practice.
Our mission is to enhance diagnostic precision and expand access to expert-level cancer care, improving patient outcomes worldwide. We’re venture-backed, early-stage, and building a team that blends deep clinical expertise with engineering intensity—moving with the rigor the medical field demands and the speed the problem deserves.
